28.3.2023 08:15:00 CEST | Monsenso |
Investor Nyheder
Nyt innovationsprojekt vil give patienter med depression lettere adgang til digital behandling med brug af Monsensos digitale sundhedsplatform. Projektet skal gøre det muligt at bruge kunstig intelligens i screening af patienter og leveringen af behandling, så tilbuddet i langt højere grad tilpasses den enkelte.
Investornyhed nr. 1-2023
København, den 28. marts 2023
Flere end en milliard mennesker har psykiske lidelser ifølge WHO, og selv i Vesteuropa modtager kun halvdelen af borgere med angst eller depression relevant behandling. Samtidigt udfordres sundhedsvæsnet af mangel på sundhedspersonale.
Derfor vil et nyt forsknings- og innovationsprojekt udvikle en digital behandling baseret på Monsensos sundhedsløsning til personer med depression, hvor patientskabte data og kunstig intelligens tilpasser forløbet til den enkelte patients behov. Projektet er støttet af Innovationsfonden og sker i samarbejde med Region Syddanmark og University of Limerick, Irland.
Digitale programmer leverer i dag evidensbaseret behandling til borgere med depression, fx i den danske klinik Internetpsykiatrien. Forskning viser, at det har samme effekt for borgere med let til moderat depression som samtaleterapi. Potentialet er stort med tusindvis af borgere, som står på venteliste eller slet ingen relevant støtte får. Men det er en udfordring at levere et personligt tilpasset tilbud til alle. Nogle har gavn af et fuldautomatisk behandlingsprogram, andre har brug for et behandlingsprogram understøttet af en psykolog. Endelig har patienter i komplekse livssituationer brug for fysiske møder med behandlerne.
”Innovationsfondens donation gør det muligt for os at udvikle kunstig intelligens, som i samspil med Internetpsykiatriens klinik og Monsensos sundhedsløsning kan sikre, at flere hurtigt får adgang til den rette behandling. Denne næste generation af digital behandling vil gøre det meget nemmere at tilbyde et helt eller delvist digitalt behandlingsforløb, som matcher den enkeltes behov”, siger Kim Mathiasen, forskningsleder ved Center for Digital Psykiatri, som leder Personae projektet.
”Vi ser et meget stort potentiale i projektet. Det muliggør videreudvikling af vores digitale sundhedsløsning, så vi endnu bedre udnytter borgerens egne data om symptomer og livssituation til at engagere dem, tilpasse indsatsen til den enkelte og støtte kliniske beslutninger i stor skala”, siger Thomas Lethenborg, adm. direktør i Monsenso.
”De unikke, borgerskabte data, som vi får ind via screening og løbende opfølgning i Monsensos løsning og Internetpsykiatrien er et fantastisk grundlag for at udvikle, træne og validere algoritmer til automatisering af beslutningsstøtte og optimering af behandlingsforløb”, siger dr. Pepijn Van de Ven, seniorforsker ved University of Limerick.
Den primære ambition med projektet er at udvikle en intelligent tilpasning af behandlings-indholdet, så det matcher patientens symptomer og livssituation. Løsningen skal bl.a. identificere tidlige tegn på frafald i et behandlingsforløb og understøtte patienter og behandleres beslutninger om behandlingen. Den kunstige intelligens skal både indarbejdes i den offentlige klinik Internetpsykiatrien, som Center for Digital Psykiatri driver på vegne af de fem regioner, og i den danske teknologivirksomhed Monsenso, hvis digitale sundhedsløsning allerede er i brug i mere end 15 lande.
Projektet ledes af Center for Digital Psykiatri, som i dansk og international kontekst er frontløber på internetbaseret terapi i forhold til både forskning, udvikling og drift. Dette projekt kobler deres forskning og store kliniske erfaring med kompetencerne og den kommercielle platform hos Monsenso samt de unikke kompetencer inden for kunstig intelligens hos University of Limerick, Irland.
Projektet, som overordnet blev omtalt ved tildelingsbeslutningstidspunktet i Selskabsmeddelelse 15-2022, er der nu underskrevet aftaler omkring, og projektet starter 1. maj 2023. Det påvirker ikke Monsensos tidligere udmeldte finansielle forventninger, men vil bidrage til at sikre væksten i 2023 og fremefter.
Fakta
Samlet budget: 22,1 mio. kr.Innovationsfondens investering: 16,5 mio. kr.Nettobidrag til Monsenso: 3,9 mio. kr Varighed: 4 årOfficiel titel: Personae – Personalised Digital Treatment of Depression
Om partnerne i projektet
Center for digital Psykiatri, Region Syddanmark, arbejder for at alle danskere får let og lige adgang til mental sundhed. Center for Digital Psykiatri er, i dansk og international kontekst, frontløbere i brugen af digitale løsninger til mental sundhedsfremme og psykiatrisk behandling og de er eksperter i at matche psykiatriens aktuelle behov med den rigtige digitale teknologi.
University of Limerick, Department of Electronic & Computer Engineering, Faculty of Science and Engineering har høj ekspertise inden for forskning og undervisning i informationskommunikationsteknologi. Department of Electronic & Computer Engineering er førende inden for forskning om kunstig intelligens til internetbaseret terapi.
Odense Universitetshospital, Depressionsforeningen og det strategiske innovationsbureau Is It a Bird er ligeledes med i projektet.
Yderligere oplysninger:
Monsenso:
CEOThomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF A/SJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning til brug for decentaliserede forsøg, patientmonitorering og behandlingsunderstøttelse. Vores mission er at bidrage til bedre sundhed til flere personer og lavere omkostninger ved at understøtte behandling digitalt og bedre udnytte patienters egne data. Vores løsning bidrager til optimering af behandlingen og giver et detaljeret overblik over patienters sundhed via indsamling af data om deres tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig intervention. Vi samarbejder med sundhedsvæsenet, medicinalindustrien og forskningsinstitutioner verden over i vores forsøg på at levere løsninger som passer ind i patienters og sundhedsprofessionelles hverdag. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
28.3.2023 08:15:00 CEST | Monsenso |
Investor News
A new innovation project “Personae” will provide easier access to personalised digital treatment for patients with depression through Monsenso's digital health platform. The project leverages patient-reported outcomes and AI to screen patients and to deliver a treatment tailored to the individual patients' needs.
Investor news no. 1-2023
Copenhagen, 2023.03.27
According to the WHO, more than one billion people worldwide have mental disorders, but the number of individuals receiving help is alarmingly low. In Western Europe, for instance, only half of the citizens with anxiety or depression receive relevant treatment. At the same time, the healthcare system is challenged by a shortage of healthcare professionals.
Therefore, Innovation Fund Denmark is funding the development of a personalised treatment based on Monsenso’s digital health solution, which will leverage artificial intelligence to tailor the treatment to the individual patient’s needs.
Today, digital programs provide evidence-based treatment to citizens with depression, for example in the Danish clinic ” Internetpsykiatrien”. Research shows that such programs have the same effect for citizens with mild to moderate depression as physical therapy sessions. The potential is huge, with thousands of citizens on waiting lists or receiving no relevant support at all. However, delivering a personalised intervention to everyone is challenging. Some patients benefit from a fully automated, digital treatment program, others need their treatment program supported by a psychologist, and yet other patients with complex life situations need physical meetings with their healthcare providers.
“The project enables us to use artificial intelligence, which, in collaboration with Monsenso’s digital health solution and the Internetpsykiatrien, can ensure that more people can quickly get access to the right treatment. This next generation of digital treatment will make it much easier to offer a fully or partially digital treatment that matches each individual’s needs,” says Kim Mathiasen, research director at the Center for Digital Psychiatry, who leads the Personae project.
”We see great potential in this project. It enables us to continue the development of our digital health solution and further validate it. It will improve the way we use people’s own health and behavioral data to keep them engaged, customise their treatment and support clinical decision-making at scale”, says Thomas Lethenborg, CEO at Monsenso.
”The unique, patient-reported data that will be generated from the screening and continuous use of Monsenso’s solution in Internetpsykiatrien is a fantastic foundation for development, training and validation of algorithms for automatisation of decision support and optimisation of treatment pathways”, says Pepijn Van de Ven, Professor at Limerick University.
The primary ambition of the project is to develop intelligent adaptations of treatment content to match patients’ symptoms and life situations. The solution should be able to identify early signs of drop-out and support patients’ and healthcare providers’ decisions concerning treatment. The artificial intelligence solutions will be incorporated into both the public Internetpsykiatrien clinic, which the Center for Digital Psychiatry operates, and into the digital health solution of Monsenso.
The project is led by the Center for Digital Psychiatry, which, in Danish and international contexts, is a pioneer in internet-based therapy in terms of development, research, and operation. This project combines their research and extensive clinical experience with the competencies and commercial platform of Monsenso, as well as the unique competencies in artificial intelligence for mental health at the University of Limerick.
Investment and collaboration agreements for the project, previously mentioned in company announcement 15-2022 at receipt of grant letter, have now been signed and the project is starting on May 1, 2023. The project does not impact Monsenso’s financial expectations for 2023, but is expected to contribute to the growth in 2023 and beyond.
Facts
Project title: Personae – Personalised Digital Treatment of DepressionTotal budget: DKK 22.1 mio.Innovation Fund Denmark investment: DKK 16.5 mio.Net contribution to Monsenso: DKK 3.9 mio.Duration: 4 years
About the partners
Center for Digital Psychiatry at Region Southern Denmark works to ensure that all Danes have easy and equal access to mental health. In a Danish and international context, the Center for Digital Psychiatry are frontrunners in the use of digital solutions for mental health promotion and psychiatric treatment and they are experts in matching the current needs of psychiatry with the right digital technology.
The University of Limerick, Department of Electronic & Computer Engineering, has high expertise in research and teaching in information and communication technology. The Department of Electronic & Computer Engineering is a leader in research on artificial intelligence for Internet-based therapy.
Odense University Hospital, the Danish Depression Association and the strategic innovation agency Is It a Bird are also involved in the project.
Further information:
Monsenso:
CEOThomas LethenborgTel. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF A/SJohn NordenTel. +45 20 72 02 00E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
